Introduction

Stomach cancer, also commonly referred to as  gastric cancer , remains one of the most significant oncological health burdens worldwide. Despite advances in detection and treatment, it ranks among the leading causes of cancer-related mortality, particularly in Asia-Pacific and parts of Europe. Continued innovations in diagnostics, targeted therapies, and immunotherapies are shaping the market dynamics, driving substantial growth and investment opportunities.

Market Size & Forecast

The global stomach cancer market was valued at approximately  USD 4.3–7.0+ billion in 2025–26  across treatment and diagnostic segments, with consistent growth projected over the next decade. Depending on the source and market scope:

• Some reports estimate the treatment segment alone at  ~USD 7.05–8.2 billion in 2025–26 , growing to over  USD 31+ billion by 2034  at a strong CAGR (~18%) through 2034.

• Broader analyzes (including diagnostics and therapy combined) place the  stomach/gastric cancer market size at USD 4.35 billion in 2025 , with forecasts reaching  around USD 10.5 billion by 2035  at a near-9% CAGR.

• Gastric cancer diagnostics alone accounted for about USD 1.32 billion in 2025, with further significant expansion expected.

These figures illustrate both the commercial scale and growth potential of the stomach cancer market through 2030+.

Get Your Sample Report Here:https://straitsresearch.com/report/stomach-cancer-market
Buy Report Now:https://straitsresearch.com/report/stomach-cancer-market/request-sample
Download full report:https://straitsresearch.com/buy-now/stomach-cancer-market

Key Market Segments

1. By Diagnosis

• Imaging Tests: CT scans, MRI, PET scans are growing fastest due to demand for non-invasive staging and monitoring.

• Biomarker & Molecular Diagnostics: Companion diagnostics (e.g., HER2, PD-L1, MSI profiling) are enabling personalized therapy.

2. By Treatment Type

• Surgery: Continues to be the most revenue-generating segment, particularly for localized disease.

• Targeted Therapy & Immunotherapy: Rapid adoption of PD-1/PD-L1 inhibitors and HER2-directed therapies is driving growth.

• Chemotherapy: Still a core treatment modality but gradually shifting toward combination regimens.

3. Regional Dynamics

• Asia-Pacific: Largest share of cases and market revenue owing to the high incidence of the disease.

• North America & Europe: Strong R&D, access to advanced therapeutics, and reimbursement frameworks foster market growth.

Latest Market Trends

Precision & Personalized Medicine

The market is experiencing a steady shift towards precision oncology, tailoring treatments based on genetic and molecular tumor profiles. Biomarker-driven approaches are becoming mainstream, improving therapeutic outcomes and reducing side effects.

Immunotherapy and Combination Regimens

Adoption of immune checkpoint inhibitors (e.g., PD-1/PD-L1 therapies) and combination regimens integrating immunotherapy with chemotherapy are increasingly used, significantly improving survival metrics.

AI & Advanced Diagnostics

Innovations such as AI-enabled early cancer detection systems are enhancing diagnostic accuracy and speed, improving the landscape for early intervention.

Rise of Biosimilars & Cost Accessibility

Patent expirations and the launch of biosimilars are expected to reduce treatment costs and broaden market access, particularly in price-sensitive regions.

Market Challenges

Late-Stage Diagnosis

Gastric cancer is often diagnosed at advanced stages, especially in developing nations, hampering effective treatment and increasing mortality rates.

High Treatment Costs

Advanced immunotherapies and targeted drugs remain expensive, limiting access for many patients, particularly without comprehensive insurance coverage.

Market Disparities

Variability in clinical outcomes and regional disparities in healthcare infrastructure pose significant challenges to standardized care delivery.

Opportunities in the Market

Emerging Markets Expansion

Growing healthcare investments in Asia-Pacific and Latin America present substantial opportunities for expanding screening and treatment adoption.

Technological Advancements

Integration of AI, telemedicine, and next-generation sequencing in diagnostics and treatment supports more effective clinical decision-making.

Clinical Trial Growth

Decentralized clinical trials and digital platforms are enhancing patient recruitment and accelerating drug development timelines, expanding therapeutic pipelines.

Top Players & Recent Developments (2025–26)

Major Industry Leaders

• F. Hoffmann-La Roche Ltd. – Trastuzumab and emerging targeted agents.

• Merck & Co., Inc. – Keytruda (pembrolizumab) and novel PD-1 combinations.

• Eli Lilly & Company – Ramucirumab and pipeline expansions.

• Pfizer, AstraZeneca, Novartis, Bristol-Myers Squibb, Daiichi Sankyo, Taiho Pharmaceutical – Active in research and combination immuno-oncology regimens.

2025 & 2026 Highlights

• Roche’s global screening initiatives and companion diagnostic expansions.

• Continued collaborations (e.g., AstraZeneca & Daiichi Sankyo) to develop next-gen targeted therapies.

• Growth in biosimilar development partnerships and co-development deals targeting Asian oncology markets.

• Notable clinical successes and trial results prompting regulatory submissions, such as promising new combinatorial immuno-therapies anticipated for approval in 2026.

Impact of Global Situation (2025–26)

The ongoing global emphasis on preventive healthcare, early detection, and cancer research funding has catalyzed both public and private sector investments. However, geopolitical variances and healthcare inequality have underscored the importance of localized strategies, especially in underserved regions. The post-pandemic healthcare focus has also increased screening participation and digital health adoption.

Trending FAQs Related to the Stomach Cancer Market

Q1. What are the major growth drivers of the stomach cancer market?
Rising incidence worldwide, adoption of precision oncology, advanced immunotherapies, and AI-enabled diagnosis are primary growth drivers.

Q2. Which geographic region holds the largest market share?
Asia-Pacific currently commands the largest market share, reflecting high incidence and growing healthcare investments.

Q3. How is personalized medicine influencing the market?
Personalized medicine, including biomarker-guided therapies and companion diagnostics, is improving treatment efficacy and patient outcomes.

Q4. What are the biggest challenges facing market expansion?
High treatment costs, delayed diagnosis, limited access in emerging markets, and variability in clinical responses are key challenges.

Q5. Which therapies are expected to dominate future treatment?
Targeted therapies, immunotherapies (PD-1/PD-L1 inhibitors), and combination regimens are projected to dominate due to better survival outcomes.

About Us:
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.